Friend MTS, Leading Global Provider of Content Protection Services, Announces Appointment of Derek Chang to Chief Executive Officer
2.6.2021 14:00:00 EEST | Business Wire | Press release
Friend MTS is pleased to announce the appointment of Derek Chang to Chief Executive Officer (CEO). A seasoned industry executive with a career spanning three decades, Chang previously served as CEO of NBA China, and has held leadership positions with several recognized sports, media and entertainment providers. He will be based in London.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005316/en/
Derek Chang, Chief Executive Officer, Friend MTS (Photo: Business Wire)
“It is my privilege to join Friend MTS as we ramp up our innovation of the technology essential to protect the needs of a complex global media industry,” said Chang. “We are at the forefront of rapid changes in consumer behavior, new business models and technology, and will ensure that creators, owners and distributors worldwide will have the formidable tools necessary to protect their valuable content.”
The announcement was made today by Jonathan Friend, Founder, Friend MTS, who previously served as CEO. A visionary in the field of content protection technologies, Friend will serve as Chief Product Officer (CPO) and continue to drive growth through the creation of the company’s advanced proprietary solutions.
“As we continue to innovate with groundbreaking solutions that our valued customers and partners have come to expect, now is the time to transition to our next leader and we are thrilled to welcome Derek to the helm of Friend MTS,” said Friend. “With deep expertise in the global sports and entertainment space, Derek brings invaluable insight to leveraging technology to create an impactful footprint for an ever-evolving media and content ecosystem.”
Prior to leading NBA China’s business, Chang was Head of International Lifestyle Channels for Scripps Networks Interactive, and had served as Executive Vice President, Content, DIRECTV. He also held senior roles for Charter Communications, the YES Network and TCI Communications. Chang currently serves on the board of directors for Liberty Media Corp. and Isos Acquisition Corp., and formerly served on the board of Starz.
Chang was named one of the “50 Most Influential People in Sports Business” by Sports Business Journal, as well as Cablefax Magazine's “Top 100 Executives in Cable.” He holds an MBA from Stanford University and a bachelor's degree in history from Yale University. He is a member of the Committee of 100 and serves on the advisory board of Row New York.
For press use, Friend MTS photo assets can be downloaded here. For more information, please visit www.friendmts.com or follow on LinkedIn and Twitter.
About Friend MTS:
Friend MTS is a leading global provider of innovative content protection technology solutions developed to advance a complex and ever-evolving media industry in collaboration with content owners, broadcasters and operators. With a comprehensive suite of advanced proprietary services ranging from content monitoring, fingerprinting and watermarking to enforcement and IP blocking, Friend MTS provides an end-to-end approach to disrupt real-world piracy and safeguard a worldwide entertainment and media market into the future. Playing an important role in social responsibility, Friend MTS has gifted organizations like the U.S. Department of Homeland Security and the International Center for Missing and Exploited Children (ICMEC) with its award-winning technology to help combat online child abuse. Founded in 2000, Friend MTS is privately held and headquartered in Birmingham, U.K. and Philadelphia, Pennsylvania, with operations throughout Europe, Asia, the Middle East, Africa, Latin America and North America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005316/en/
Contact information
Friend MTS Media Contact:
Nora Ellish
+1 (917) 744-9200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
